TY  - JOUR
AU  - Horn, Leora
AU  - Spigel, David R
AU  - Vokes, Everett E
AU  - Holgado, Esther
AU  - Ready, Neal
AU  - Steins, Martin
AU  - Poddubskaya, Elena
AU  - Borghaei, Hossein
AU  - Felip, Enriqueta
AU  - Paz-Ares, Luis
AU  - Pluzanski, Adam
AU  - Reckamp, Karen L
AU  - Burgio, Marco A
AU  - Kohlhäeufl, Martin
AU  - Waterhouse, David
AU  - Barlesi, Fabrice
AU  - Antonia, Scott
AU  - Arrieta, Oscar
AU  - Fayette, Jérôme
AU  - Crinò, Lucio
AU  - Rizvi, Naiyer
AU  - Reck, Martin
AU  - Hellmann, Matthew D
AU  - Geese, William J
AU  - Li, Ang
AU  - Blackwood-Chirchir, Anne
AU  - Healey, Diane
AU  - Brahmer, Julie
AU  - Eberhardt, Wilfried E E
PY  - 2017
DO  - 10.1200/JCO.2017.74.3062
UR  - http://hdl.handle.net/10668/11674
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier:...
LA  - en
KW  - Antibodies, Monoclonal
KW  - Antineoplastic Agents
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Docetaxel
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lung Neoplasms
KW  - Nivolumab
KW  - Survival Rate
KW  - Taxoids
KW  - Treatment Outcome
TI  - Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
TY  - research article
VL  - 35
ER  -